Analysts' Actions: CSCO, COP, GOOG, FDX
NEW YORK (TheStreet) -- CHANGE IN RATINGS
Adobe Systems (ADBE) downgraded at JMP from Market Perform to Underperform, JMP Securities said. $26 price target. Company cut its sales outlook and has exposure to Europe.
Acme Packet (APKT) downgraded at Jefferies to Hold from Buy, Jefferies said. $21 price target. Hesitation by carriers to invest in wireline.
Beam (BEAM) upgraded at Argus from Hold to Buy, Argus said. $74 price target. Company could be a possible takeover target.
Choice Hotels (CHH) upgraded at Baird from Underperform to Neutral, Robert Baird said. $38 price target. Company is returning cash to shareholders and shorts may soon be scrambling to cover.
Colony Bankcorp (CBAN) upgraded to hold at TheStreet Ratings.
Rockwell Collins (COL) downgraded at Goldman to Sell, Goldman Sachs said. Company is facing increased competition and has high exposure to the defense sector. $46 price target.
ConocoPhillips (COP) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Valuation call, based on a $58 price target.
Cisco (CSCO) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $21 price target. Solid, growing cash flow deserves a higher multiple.
Citrix Systems (CTXS) rated new Hold at ThinkEquity. $84 price target. Company faces growth risks in Europe.
Coventry Health (CVH) downgraded at Leerink to Market Perform, Leerink Swann said. Risk/reward is less favorable, ahead of the Supreme Court decision on healthcare reform.
Community Health (CYH) rated new Buy at UBS. $36 price target. Leader in non urban hospital market with a growth track record.
Huntington Bancshares (HBAN) rated new Neutral at JP Morgan. Company still lags in several key metrics. $7 price target.
HCA Holdings (HCA) rated new Buy at UBS. $34 price target. Nation's largest healthcare provider focused on fast growing markets.
Huntington Ingalls (HII) upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $39 price target. Navy demand should remain strong, relative to other areas of defense.
Health Management (HMA) rated new Buy at UBS. $11 price target. Leading hospital operator in fast growing southeast non-urban market.